| Document |
Document Title |
|
WO/2024/070614A1 |
This test container is used for a nucleic acid amplification test executed in a nucleic acid amplification device. The test container comprises: a substrate; and a flowpath which is provided to the substrate and in which a sample contain...
|
|
WO/2024/065083A1 |
Disclosed in the present application is a method for testing the in-vivo drug efficacy of an IL-1α antibody in non-murine mammals. The method comprises administering IL-1α from non-murine mammals and an IL-1α antibody to be tested to ...
|
|
WO/2024/067764A1 |
The present invention provides a monoclonal antibody (especially a mouse, chimeric or humanized monoclonal antibody)/bispecific antibody or an antigen-binding fragment thereof. The antibody or the antigen-binding fragment thereof specifi...
|
|
WO/2024/071099A1 |
The present invention addresses the problem of providing a novel nucleic acid molecule capable of simultaneously achieving both a high gene regulatory effect and toxicity reduction. Provided is a nucleic acid molecule that contains a b...
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/065056A1 |
Antibody-drug conjugates (ADCs) comprising an antibody construct that specifically binds c-Met conjugated to one or more drugs, such as the auristatin analogue, compound (1), via a linker. Also described are anti-cMet antibody constructs...
|
|
WO/2024/071491A1 |
The present invention relates to a microorganism having a mycosporine-like amino acid producing ability and a method for producing mycosporine-like amino acids using same. According to one aspect of the present invention, when 3-deoxy-7-...
|
|
WO/2024/067796A1 |
Provided are a non-human animal expressing a human or chimeric (e.g. humanized) IL5 and/or IL5RA protein, and a use method therefor.
|
|
WO/2024/071437A1 |
The present invention relates to an epileptic model of a mammal. This epileptic model is obtained by a method including: (i) injecting an RNA-interfering shRNA having a sequence corresponding to base 194-212 of SEQ ID NO: 1 of a nucleic ...
|
|
WO/2024/067870A1 |
Provided are a targeting vector and a method for targeting same to a host cell. The vector comprises a first molecule that binds to an endocytosis receptor of the target cell and a second molecule that promotes the release of a substance...
|
|
WO/2024/067478A1 |
The present invention provides a method for measuring a single-molecule RNA force spectrum and a use thereof. The method comprises the following steps: 1) obtaining a handle chain: designing and synthesizing a specially modified handle c...
|
|
WO/2024/073692A1 |
The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Serine Hydroxymethyltransferase 2 (SHMT2). Further provided are methods for preparing such cells and methods for using such cells...
|
|
WO/2024/068010A1 |
A first aspect of the invention relates to a nucleic acid agent capable of downregulating or inhibiting the expression or biological activity of SNX9 in a target cell, wherein the nucleic acid agent is selected from an antisense oligodeo...
|
|
WO/2024/065009A1 |
The present invention relates to methods for manipulating plants, more particularly methods for generating genetically modified plants, especially safflower plants.
|
|
WO/2024/071010A1 |
Disclosed are: a method for producing a cell population in which regulatory T cells proliferate, the method including (1) a step for culturing a cell population including pluripotent-stem-cell-derived CD4+ T cells in the presence of IL-4...
|
|
WO/2024/071429A1 |
The present invention relates to a method for preparing a double-stranded DNA library from single-stranded DNA fragments and provides a highly efficient library preparation method, etc., that generates or contains few adapter dimers. The...
|
|
WO/2024/067776A1 |
Provided herein are a nucleic acid construct encoding an anti-VEGF fusion protein, such as an expression vector, as well as a recombinant virus such as a recombinant lentivirus and a recombinant adeno-associated virus prepared by the con...
|
|
WO/2024/073732A1 |
One aspect of the present disclosure relates to a dsRNA agent comprising a sense strand and an antisense strand sufficiently complementary to at least one portion of a mRNA of the target gene, each strand having 14 to 40 nucleotides, whe...
|
|
WO/2024/073686A1 |
The present disclosure provides an isolated mammalian cell comprising a reduced or eliminated expression of Phosphoserine Phosphatase (PSPH). Further provided are methods for preparing such cells and methods for using such cells for the ...
|
|
WO/2024/071388A1 |
The present invention addresses the problem of providing a novel enzyme agent containing an aminopeptidase that exhibits different substrate specificity from conventional products. The present invention relates to an enzyme agent having ...
|
|
WO/2024/066941A1 |
Provided is a composition for detecting bladder cancer. The composition comprises a detection reagent for detecting at least one of the following methylation sites: cg00206063, cg03278514, and cg13314394. Also provided are use of the com...
|
|
WO/2024/068971A1 |
Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain low error rate, low phasing rate, or increased incorporation rate for a s...
|
|
WO/2024/073397A1 |
This invention relates synthetic tetraspanin proteins comprising a heterologous protein or fragment thereof inserted within the second extracellular loop of a tetraspanin backbone, wherein the heterologous protein or fragment thereof is ...
|
|
WO/2024/071382A1 |
The present invention addresses the problem of providing a pluripotent stem cell and a cell (especially, an endothelial cell) differentiated and induced from a stem cell, to which a new function is imparted. The pluripotent stem cell hav...
|
|
WO/2024/073733A2 |
The present disclosure provides, in part, methods of eliciting immuno-tolerance using truncated membrane-bound and soluble immune checkpoints. Constructs comprising the immune checkpoint protein or portions thereof capable of binding to ...
|
|
WO/2024/066616A1 |
Provided is a high-affinity PD1 protein conjugate, which comprises an elastin-like polypeptide and a high-affinity PD1 protein connected to the elastin-like polypeptide. The conjugate significantly improves the biological half-life and b...
|
|
WO/2024/073756A2 |
A composition, a method for selectively altering expression of a gene, and a method of selectively modulating activity of a Cas protein is provided. The composition includes a nucleotide regulator wherein the regulator is an oligonucleot...
|
|
WO/2023/150696A9 |
Provided is a recombinant milk protein for delivery of a hydrophobic bioactive agent, a composition comprising such recombinant milk protein, and a method for using such composition.
|
|
WO/2024/072224A2 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/068674A1 |
The present disclosure provides complexes and methods of use. In some embodiments, a complex described herein is a complex comprising a cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and ...
|
|
WO/2024/073043A1 |
Provided herein are methods, compositions, and kits related to using a CpG binding protein. In one embodiment, the present disclosure includes methods, compositions, and kits related to using a CpG binding protein with a cytidine deamina...
|
|
WO/2024/066165A1 |
Provided are an affinity maturation method and an anti-human PD-L1 single-domain antibody affinity maturation, relating to the field of biomedicine and antibody engineering. The antibody affinity maturation method of the present inventio...
|
|
WO/2024/068795A1 |
The present invention provides a method of releasing viral vectors from cells producing those viral vectors by contacting the cells with a photosensitising agent which is then irradiated to disrupt the plasma membrane of the cells to rel...
|
|
WO/2024/069010A1 |
Subject matter of the present invention is a delivery vector comprising a DNA sequence encoding pre-prodynorphin or pre-prodynorphin-variants and wherein said delivery vector drives expression of a pre- propeptide in a target cell, and w...
|
|
WO/2024/067762A1 |
Provided are anti-GCC single domain antibodies (e. g., VHH domain antibodies), and chimeric antigen receptors (CARs) that bind to GCC comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellula...
|
|
WO/2024/067774A1 |
The present invention relates to saccharomyces cerevisiae engineering bacteria for improving a gene expression level and a construction method and application thereof. The saccharomyces cerevisiae W303-1a is used as an original strain. A...
|
|
WO/2024/071964A1 |
The present invention relates to: a fusion polypeptide in which a His tag is fused with a peptide tag having main amino acids composed of charged and polar amino acids; a fusion protein in which the fusion polypeptide is fused with a tar...
|
|
WO/2024/073734A2 |
Pharmacological or genetic inactivation of MAGL reduces neuroinflammation and neuropathology in animal models of AD. However, global inactivation of MAGL induces functional tolerance of CB1R, which reduces the effectiveness of pharmacoth...
|
|
WO/2024/071362A1 |
The present invention addresses the problem of providing a new method for improving the delivery efficiency of a drug such as a nucleic acid drug to the nervous system. Provided is a delivery enhancer for enhancing the delivery of a dr...
|
|
WO/2024/065995A1 |
The present invention belongs to the technical field of detection, and particularly relates to a method, system and kit for in-situ detection of extracellular vesicle-carried miRNA. The present invention provides a method for in-situ det...
|
|
WO/2024/067192A1 |
A linear displacement isothermal amplification (LDIA) method and use thereof are provided. Specifically, an initial reaction of LDIA is started for four common primers of a template, including a pair of outer primers (LOF and LOR) and a ...
|
|
WO/2024/073386A1 |
An implantable medical device is provided. The implantable medical device includes a core having an antisense oligonucleotide (ASO) dispersed within a core polymer matrix. The core polymer matrix includes an ethylene vinyl acetate copoly...
|
|
WO/2024/068995A1 |
The invention relates to a novel functional transposase system. More specifically, the invention relates to a DNA transposon comprising a heterologous polynucleotide flanked by transposon flanking regions and to a recombinant transposase...
|
|
WO/2024/067222A1 |
CD3-targeting antibodies and bispecific antibodies targeting both CD3 and tumor-associated antigens. Polynucleotides encoding the antibodies, pharmaceutical compositions comprising the antibodies, and methods of producing the antibodies ...
|
|
WO/2024/071112A1 |
The present invention provides a method for producing an antibody comprising a combination of a VL domain and a VH domain having high affinity with respect to an antigen. The present invention pertains to a method comprising: setting mul...
|
|
WO/2024/068997A2 |
The present invention relates to antisense oligonucleotides (oligomers) complementary to NAT8L pre-mRNA and mRNA and which are capable of inhibiting the expression of NAT8L. Inhibition of NAT8L expression is beneficial for the treatment ...
|
|
WO/2024/012435A9 |
The present disclosure generally relates to gene editing systems and methods for treating hereditary angioedema (HAE). Also disclosed are polynucleotides, vectors, cells, kits and compositions comprising the components of the gene editin...
|
|
WO/2024/071970A1 |
The present invention relates to: a fusion polypeptide comprising a His tag, and a peptide tag of which the main amino acids are charged amino acids; a fusion protein in which the fusion polypeptide and a target protein are fused; and a ...
|
|
WO/2024/067876A1 |
The present invention generally relates to novel anti-FGFR2b antibodies and antigen-binding fragments thereof, which specifically bind fibroblast growth factor receptor 2b (FGFR2IIIb, or FGFR2b), and polynucleotides, vectors, cells, comp...
|
|
WO/2024/070874A1 |
The purpose of the present invention is to provide a monoclonal antibody that binds to A1 beta-casein or to both A1 beta-casein and A2 beta-casein and to provide a method for detecting A1 beta-casein using said monoclonal antibody. The m...
|
